Genzyme General Division (GENZ)

(A Top Pick Jan 12/05. Down 1%.) The bio-techs are about the best performing group over the last little while. Diversified product line. Have a great revenue line. Still likes.

(Top Pick Jan 12/05. Down 6%.) The pharmaceutical group has been out of favor. Has some good revenue growth.

Has grown very well over the last 3 years against an industry that's had a difficult time. Risk level is relatively low. A better way to develop new drugs as opposed to the old line drug companies.